Dozens of opportunities for US generic competition have been highlighted by the US Food and Drug Administration in the latest update to the agency’s list of off-patent products without exclusivities that nevertheless have no approved generic rivals.
The list of approved new drug application drug products that are no longer protected by patents or exclusivities, and for...




